Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3341-3347

  Tauchi, Tetsuzo ^a   Nakajima, Akihiro ^a   Sashida, Goro ^a   Shimamoto, Takashi ^a   Ohyashiki, Junko H ^a   Abe, Kenji ^b   Yamamoto, Kohtaro ^b   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; TELOMERASE; PROTEIN TYROSINE KINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

APOPTOSIS; ARTICLE; CELL DIVISION; CELL STRAIN K 562; DRUG ANTAGONISM; FLOW CYTOMETRY; HUMAN; LEUKEMIA; METABOLISM; TELOMERE; TIME; CELL IMMORTALIZATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSFORMATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN CELL; LEUKEMIA CELL; MORPHOLOGY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TELOMERASE; TELOMERE; TIME FACTORS;

EID: 0036845833     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Tauchi, T., and Broxmeyer, H. E. BCR/ABL signal transduction. Int. J. Hematol., 61: 105-112, 1995
2. Konopka, J. B., Watanabe, S. M., and Witte, O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 37: 1035-1042, 1984
3. Kloetzerl, W., Kurzrock, R., Smith, L., Talpaz, M., Spiller, M., Gutterman, J., and Arlinghaus, R. The human cellular abl gene product in chronic myelogenous leukemia cell line K562 has an associated tyrosine kinase activity. Virology, 140: 230-238, 1985
4. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL-positive cells. Nat. Med., 2: 561-566, 1996
5. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Capdeville, R., and Talpaz, M. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001
6. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in blastic crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia. N. Engl. J. Med., 344: 1038-1042, 2001
7. Nakajima, A., Tauchi, T., and Ohyashiki, K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia (Baltimore), 15: 989-990, 2001
8. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, N., and Sawyers, C. L. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001
9. Blackburn, E., and Greider, C. (eds.). Telomeres. New York: Cold Spring Harbor Laboratory Press, 1995
10. van Steensel, B., Smogorzewska, A., and de Lange, T. TRF protects human telomeres from end-to-end fusions. Cell, 92: 401-413, 1998
11. de Lange, T., and Jacks, T. For better or worse? Telomerase inhibition and cancer. Cell, 98: 273-275, 1999
12. Harley, C. B. Telomere loss: Mitotic clock or genetic time bomb? Mutat. Res., 256: 271-282, 1991
13. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. Science (Wash. DC), 279: 349-352, 1998
14. Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., and Klingelhutz, A. J. Both Rb/p161NK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (Lond.), 396: 84-88, 1998
15. Jiang, X. R., Jimenetz, G., Chang, E., Frolkis, M., Kusler. B., Sage, M., Beeche, M., Bodnar, A. G., Wahl, G. M., Tlsty, T. D., and Chiu, C. P. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat. Genet., 21: 111-114, 1999
16. Morales, C. P., Holt, S. E., Ouellette, M., Kaur, K. J., Yan, Y., Wilson, K. S., White, M. A., Wright, W. E., and Shay, J. W. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet., 21: 115-118, 1999
17. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. Creation of human tumor cells with defined genetic elements. Nature (Lond.), 400: 464-468, 1999
18. Wang, J., Hannon, G. J., and Beach, D. H. Risky immortalization by telomerase. Nature (Lond.), 405: 401-402, 2000
19. Weitzman, J. B., and Yaniv, M. Rebuilding the road to cancer. Nature (Lond.), 400: 401-402, 1999
20. Hahn, C. W., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170. 1999
21. Zhang, X., Mar, V., Zhou, W., Harrington, L., and Robinson, M. O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev., 13: 2388-2399, 1999
22. Ohyashiki, K., Miyauchi, J., Ohyashiki, J. H., Saito, M., Yaguchi, M., Inatomi, Y., Nakazawa, S., Waca, H., Mizutani, S., Matsuo, Y., and Toyama, K. Interleukin-7 enhances colony growth and induces CD20 antigen of a Ph-positive acute lymphoblastic leukemia cell line, OM9; 22. Leukemia (Baltimore), 7: 1034-1040, 1993
23. Tauchi, T., Boswell, H. S., Leibowitz, D., and Broxmeyer, H. E. Coupling between p210 bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor-independent link to ras activation pathway. J. Exp. Med., 179: 167-175, 1994
24. Ohyashiki, J. H., Ohyashiki, K., Toyama, K., and Shay, J. W. A nonradioactive, fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. Trends Genet., 12: 395-396, 1996
25. Nishimaki, J., Miyazawa, K., Yaguchi, M., Katagiri, T., Kawanishi, Y., Toyama, K., Ohyashiki, K., Hashimoto, S., Nakaya, K., and Takiguchi, T. Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation. Leukemia (Baltimore), 13: 1399-1405, 1999
26. Kilian, A., Bowtell, D. D., Abud, H. E., Hime, G. R., Venter, D. J., and Keese, P. K., Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet., 6: 2011-2019, 1997
27. Ulaner, G. A., Hu, J. F., Vu, T. H., Giudice, L. C., and Hoffman, A. R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternative splicing of hTERT transcripts. Cancer Res., 58: 4168-4172, 1998
28. Wick, M., Zubov, D., and Hagen, G. Genomic organization and promoter characterization of gene encoding the human telomerase reverse transcriptase (hTERT). Gene (Amst.), 232: 97-106, 1999
29. Colgin, L. M., Wilkinson, C., Englesou, A., Kilian, A., Robinson, M. O., and Reddel, R. R. The hTERTa splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia, 2: 426-432, 2000
30. Aisner, D. L., Wright, W. E., and Shay, J. W. Telomerase regulation: Not just flipping the switch. Curr. Opin. Genet. Dev., 12: 8O-85, 2002
31. Linger, J., Hughes, T. R., Schevchenko, A., Mann, M., Lundblad, V., and Cech. T. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science (Wash. DC), 276: 561-567, 1997
32. Iwama, H., Ohyashiki, K., Ohyashiki, J. H., Hayashi, S., Kawakubo, K., Shay, J. W., and Toyama, K. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myelogenous leukemia. Cancer (Phila.), 79: 1552-1560, 1997
33. Ohyashiki, K., Ohyashiki, J. H., Iwama, H., Hayashi, S., Shay, J. W., and Toyama, K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia (Baltimore), 11: 190-194, 1997
34. Ohyashiki, J. H., Sashida, G., Tauchi, T., and Ohyashiki, K. Telomeres and telomerase in hematologic neoplasis. Oncogene, 21: 680-687, 2002
35. Sachsinger, J., Gonzalez-Suarez, E., Samper, E., Heicappell, R., Muller, M., and Blasco, A. Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells. Cancer Res., 61: 5580-5586, 2001
36. Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., and Reddel, R. R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J., 14: 4240-4248, 1995
37. Dunham, M. A., Neumann, A. A., Fasching, C. L., and Reddel, R. R. Telomere maintenance by recombination in human cells. Nat. Genet., 4: 447-450, 2000
38. Henson, J. D., Neumann, A. A., Yeager, T., and Reddel, R. P. Alternative lengthening of telomeres in mammalian cells. Oncogene, 21: 598-610, 2002
39. Shin-ya, K., Wierzba, K., Matsuo, K., Yamada, Y., Furihata, K., Hayakawa, Y., and Seto, H. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J. Am. Chem. Soc., 123: 1262-1263, 2001
40. Lee, K. H., Rudolph, K. L., Ju, Y. J., Greenberg, R. A., Cannizzaro, L., Chin, L., Weiler, S. R., and DePinho, R. A. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc. Natl. Acad. Sci. USA, 98: 3381-3386, 2001
41. Maida, Y., Kyo, S., Kanaya, T., Wang, Z., Yatabe, N., Tanaka, M., Nakamura, M., Ohmichi, M., Gotoh, N., Murakami, S., and Inoue, M. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene, 21: 4071-4079, 2002
42. Sawyers, C. L., McLauglin, J., Goga, A., Havlik, M., and Witte, O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell, 77: 121-131, 1994
43. Kharbana, S., Kumar, V., Dhar, S., Pandey, P., Chen, C., Majumder, P., Yuan, Z-M., Whang, Y., Stauss, W., Pandia, T. K., Weaver, P. D., and Kufe, D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr. Biol., 10: 568-575, 2000
44. Vigneri, P., and Wang, J. Y. J. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med., 7: 228-234, 2001
45. Baur, J. A., Zou, Y., Shay, J. W., and Wright, W. E. Telomere position effect in human cells. Science (Wash. DC), 292: 2075-2077, 2001
46. Artandi, S. E., Chang, S., Lee, S. L., Alson, S., Golllieb, G. D., Chin, L., and DePinho, R. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature (Lond.), 406: 641-645, 2000
47. Wright, W. E., and Shay, J. W. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat. Med., 6: 849-851, 2000